CERUS CORP (CERS)

US1570851014 - Common Stock

2.225  -0.02 (-0.67%)

Fundamental Rating

2

Overall CERS gets a fundamental rating of 2 out of 10. We evaluated CERS against 199 industry peers in the Health Care Equipment & Supplies industry. Both the profitability and financial health of CERS have multiple concerns. While showing a medium growth rate, CERS is valued expensive at the moment.



1

1. Profitability

1.1 Basic Checks

CERS had negative earnings in the past year.
In the past year CERS has reported a negative cash flow from operations.
CERS had negative earnings in each of the past 5 years.
In the past 5 years CERS always reported negative operating cash flow.

1.2 Ratios

CERS has a Return On Assets of -24.19%. This is comparable to the rest of the industry: CERS outperforms 46.97% of its industry peers.
CERS has a worse Return On Equity (-103.30%) than 70.20% of its industry peers.
Industry RankSector Rank
ROA -24.19%
ROE -103.3%
ROIC N/A
ROA(3y)-23.19%
ROA(5y)-29.57%
ROE(3y)-61.77%
ROE(5y)-75.64%
ROIC(3y)N/A
ROIC(5y)N/A

1.3 Margins

CERS has a Gross Margin of 62.84%. This is in the better half of the industry: CERS outperforms 63.13% of its industry peers.
CERS's Gross Margin has been stable in the last couple of years.
The Profit Margin and Operating Margin are not available for CERS so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 62.84%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-2.21%
GM growth 5Y1.41%

1

2. Health

2.1 Basic Checks

CERS does not have a ROIC to compare to the WACC, probably because it is not profitable.
CERS has more shares outstanding than it did 1 year ago.
Compared to 5 years ago, CERS has more shares outstanding
CERS has a worse debt/assets ratio than last year.

2.2 Solvency

CERS has an Altman-Z score of -4.84. This is a bad value and indicates that CERS is not financially healthy and even has some risk of bankruptcy.
With a Altman-Z score value of -4.84, CERS is not doing good in the industry: 69.70% of the companies in the same industry are doing better.
CERS has a Debt/Equity ratio of 1.24. This is a high value indicating a heavy dependency on external financing.
The Debt to Equity ratio of CERS (1.24) is worse than 83.84% of its industry peers.
Industry RankSector Rank
Debt/Equity 1.24
Debt/FCF N/A
Altman-Z -4.84
ROIC/WACCN/A
WACC10%

2.3 Liquidity

A Current Ratio of 1.88 indicates that CERS should not have too much problems paying its short term obligations.
CERS has a Current ratio of 1.88. This is in the lower half of the industry: CERS underperforms 75.25% of its industry peers.
A Quick Ratio of 1.35 indicates that CERS should not have too much problems paying its short term obligations.
With a Quick ratio value of 1.35, CERS is not doing good in the industry: 73.74% of the companies in the same industry are doing better.
Industry RankSector Rank
Current Ratio 1.88
Quick Ratio 1.35

5

3. Growth

3.1 Past

CERS shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -18.18%.
CERS shows a decrease in Revenue. In the last year, the revenue decreased by -1.23%.
The Revenue has been growing by 29.70% on average over the past years. This is a very strong growth!
EPS 1Y (TTM)-18.18%
EPS 3YN/A
EPS 5YN/A
EPS growth Q2Q40%
Revenue 1Y (TTM)-1.23%
Revenue growth 3Y26.15%
Revenue growth 5Y29.7%
Revenue growth Q2Q1.96%

3.2 Future

Based on estimates for the next years, CERS will show a very strong growth in Earnings Per Share. The EPS will grow by 20.63% on average per year.
Based on estimates for the next years, CERS will show a quite strong growth in Revenue. The Revenue will grow by 13.43% on average per year.
EPS Next Y11.26%
EPS Next 2Y24.22%
EPS Next 3Y20.63%
EPS Next 5YN/A
Revenue Next Year-5.7%
Revenue Next 2Y3.52%
Revenue Next 3Y6.47%
Revenue Next 5Y13.43%

3.3 Evolution

Although the future Revenue growth is still strong, it is not able to hold up the even more excellent growth rate of the past years.

1

4. Valuation

4.1 Price/Earnings Ratio

CERS reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Also next year CERS is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A

4.3 Compensation for Growth

A more expensive valuation may be justified as CERS's earnings are expected to grow with 20.63% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y24.22%
EPS Next 3Y20.63%

0

5. Dividend

5.1 Amount

No dividends for CERS!.
Industry RankSector Rank
Dividend Yield N/A

CERUS CORP

NASDAQ:CERS (2/22/2024, 2:20:48 PM)

2.225

-0.02 (-0.67%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Equipment & Supplies
Earnings (Last)
Earnings (Next)
Inst Owners
Inst Owner Change
Ins Owners
Ins Owner Change
Market Cap403.17M
Analysts
Price Target
Dividend
Industry RankSector Rank
Dividend Yield N/A
Dividend Growth(5Y)
DP
Div Incr Years
Div Non Decr Years
Ex-Date
Surprises & Revisions
EPS beat(2)
Avg EPS beat(2)
Min EPS beat(2)
Max EPS beat(2)
EPS beat(4)
Avg EPS beat(4)
Min EPS beat(4)
Max EPS beat(4)
EPS beat(8)
Avg EPS beat(8)
EPS beat(12)
Avg EPS beat(12)
EPS beat(16)
Avg EPS beat(16)
Revenue beat(2)
Avg Revenue beat(2)
Min Revenue beat(2)
Max Revenue beat(2)
Revenue beat(4)
Avg Revenue beat(4)
Min Revenue beat(4)
Max Revenue beat(4)
Revenue beat(8)
Avg Revenue beat(8)
Revenue beat(12)
Avg Revenue beat(12)
Revenue beat(16)
Avg Revenue beat(16)
PT rev (1m)
PT rev (3m)
EPS NQ rev (1m)
EPS NQ rev (3m)
EPS NY rev (1m)
EPS NY rev (3m)
Revenue NQ rev (1m)
Revenue NQ rev (3m)
Revenue NY rev (1m)
Revenue NY rev (3m)
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S
P/FCF
P/OCF
P/B
P/tB
EV/EBITDA
EPS(TTM)
EY
EPS(NY)
Fwd EY
FCF(TTM)
FCFY
OCF(TTM)
OCFY
SpS
BVpS
TBVpS
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -24.19%
ROE -103.3%
ROCE
ROIC
ROICexc
ROICexgc
OM N/A
PM (TTM) N/A
GM 62.84%
FCFM
ROA(3y)
ROA(5y)
ROE(3y)
ROE(5y)
ROIC(3y)
ROIC(5y)
ROICexc(3y)
ROICexc(5y)
ROICexgc(3y)
ROICexgc(5y)
ROCE(3y)
ROCE(5y)
ROICexcg growth 3Y
ROICexcg growth 5Y
ROICexc growth 3Y
ROICexc growth 5Y
OM growth 3Y
OM growth 5Y
PM growth 3Y
PM growth 5Y
GM growth 3Y
GM growth 5Y
F-Score
Asset Turnover0.9
Health
Industry RankSector Rank
Debt/Equity 1.24
Debt/FCF
Debt/EBITDA
Cap/Depr
Cap/Sales
Interest Coverage
Cash Conversion
Profit Quality
Current Ratio 1.88
Quick Ratio 1.35
Altman-Z
F-Score
WACC
ROIC/WACC
Cap/Depr(3y)
Cap/Depr(5y)
Cap/Sales(3y)
Cap/Sales(5y)
Profit Quality(3y)
Profit Quality(5y)
Growth
EPS 1Y (TTM)-18.18%
EPS 3YN/A
EPS 5Y
EPS growth Q2Q
EPS Next Y11.26%
EPS Next 2Y
EPS Next 3Y
EPS Next 5Y
Revenue 1Y (TTM)-1.23%
Revenue growth 3Y26.15%
Revenue growth 5Y
Revenue growth Q2Q
Revenue Next Year
Revenue Next 2Y
Revenue Next 3Y
Revenue Next 5Y
EBIT growth 1Y
EBIT growth 3Y
EBIT growth 5Y
EBIT Next Year
EBIT Next 3Y
EBIT Next 5Y
FCF growth 1Y
FCF growth 3Y
FCF growth 5Y
OCF growth 1Y
OCF growth 3Y
OCF growth 5Y